Bessemer Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bessemer Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16K	Buy	30 +6	+25%	+$3.07K	﹤0.01%	2060
2026 Q1	$13K	Hold	24	–	–	﹤0.01%	2047
2025 Q4	$14K	Buy	24 +19	+380%	+$9.7K	﹤0.01%	1994
2025 Q3	$2K	Hold	5	–	–	﹤0.01%	2332
2025 Q2	$2K	Hold	5	–	–	﹤0.01%	2224
2025 Q1	$2K	Sell	5 -5	-50%	-$1.64K	﹤0.01%	2250
2024 Q4	$3K	Hold	10	–	–	﹤0.01%	2137
2024 Q3	$2K	Buy	+10	New	+$2.56K	﹤0.01%	2234
2019 Q1	–	Sell	-1,033	Closed	-$116K	–	1886
2018 Q4	$116K	Buy	+1,033	New	+$160K	﹤0.01%	1125
2015 Q4	–	Sell	-16	Closed	-$1K	–	1666
2015 Q3	$1K	Buy	+16	New	+$1.16K	﹤0.01%	1546

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bessemer Group's MDGL Position: Q2 2026 in Review

Bessemer Group increased its Madrigal Pharmaceuticals (MDGL) stake by 25% in Q2 2026, buying an estimated $3.07K and bringing the position to 30 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Bessemer Group first reported a position in MDGL in Q3 2015 and has held it in 10 quarters since. The position peaked at $116K in Q4 2018. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Bessemer Group held 30 shares of Madrigal Pharmaceuticals worth $16K as of Q2 2026.
Bessemer Group bought 6 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $3.07K.
Madrigal Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2060 holding.
Bessemer Group first reported a position in Madrigal Pharmaceuticals in Q3 2015 and has held it in 10 quarters since.
Bessemer Group's Madrigal Pharmaceuticals position peaked at $116K in Q4 2018.
415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.